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Abstract 23 
The current paradigm for biomedical research and drug testing postulates that in vitro and 24 
in silico data inform animal studies that will subsequently inform human studies. Recent 25 
evidence points out that animal studies have made a poor contribution to current 26 
knowledge of Major Depressive Disorder, whereas the contribution of in vitro and in 27 
silico studies to animal studies- within this research area- is yet to be properly quantified. 28 
This quantification is important since biomedical research and drug discovery and 29 
development includes two steps of knowledge transferability and we need to evaluate the 30 
effectiveness of both in order to properly implement 3R principles (Replacement, 31 
Reduction and Refinement). 32 
Here, we used the citation tracking facility within Web of Science to locate citations of 33 
original research papers on in vitro and in silico related to MDD published identified in 34 
PubMed by relevant search terms.  35 
67 publications describing target papers were located. Both in vitro and in silico papers 36 
are more cited by human medical papers than by animal papers. 37 
The results suggest that, at least concerning MDD research, the current two steps of 38 
knowledge transferability are not being followed, indicating a poor compliance with the 39 
3R principles. 40 
Keywords: animal use alternatives, in silico, in vitro, major depressive disorder, Three Rs 41 
 42 
1. Introduction 43 
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Biomedical research heavily relies on animal studies, despite the ethical and clinical 44 
limitations of these (Herrmann, 2019). 45 
The standard contemporary paradigm for biomedical research, and drug discovery and 46 
development, requires scientists to test putative new clinical interventions, by progressing 47 
from simple to increasingly complex models, prior to conducting human studies and 48 
trials, as shown in Fig. 1.  49 
 50 
 51 
Figure 1: Current paradigm of biomedical research and drug discovery and development. 52 
Kindly provided by Taylor (2019). 53 
 54 
Even though this paradigm is more focused toward drug discovery, it is also encouraged 55 
for broader research, by legislation and guidelines pertaining to animal research, in 56 
various countries and regions (e.g.Workman et al., 2010). 57 
Supporters of animal studies within biomedical research claim that 1) it is not possible to 58 
discontinue their use, as that would jeopardize human health, and that 2) human-based 59 
methods (in silico and in vitro) are used in early steps of biomedical research to inform 60 
the animal research community, hence avoiding unnecessary or excessive use of animals. 61 
For example, purportedly, if a substance shows high levels of toxicity in vitro it will not 62 
progress into animal testing (Choudhuri et al., 2017). In the same way, a drug that shows 63 
high toxicity in animal testing should not proceed to human trials. However, it has been 64 
demonstrated that human trials may sometimes occur simultaneously with animal trials, 65 
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rather than sequentially, as one would expect if animal trials were an essential step prior 66 
to human trials (Pound et al., 2004).  67 
In our previous study we compared the number of citations  in vitro, in silico and non-68 
human primate-based (NHP) original studies focused on Major Depressive Disorder 69 
(MDD), that were received (i) in total, (ii) by unspecified human medical papers, and (iii) 70 
by human medical papers focused on MDD. We verified that both in vitro and in silico 71 
research papers received more citations by human medical papers, than NHP papers. This 72 
was unexpected, considering that most countries restrict the use of NHPs, making it 73 
reasonable to presume that when they were used, they should provide a significant 74 
contribution to human health. However, this was not the case. Data obtained via simpler 75 
models (in vitro and in silico) seemed to be more visible or considered more important 76 
by the human medical research community. This called into question the contemporary 77 
paradigm of biomedical research and drug discovery, in which knowledge is presumed to 78 
transfer between animal and human models (Carvalho et al., 2019a).  79 
Considering that this paradigm presumes two steps of knowledge transferability: i) 80 
between simpler and complex models, and ii) between animals models and humans, we 81 
wondered if there could be knowledge transferability problems in step (i), similar to those 82 
we demonstrated at step (ii). 83 
Hence, the aim of the current study is to assess whether in vitro and in silico papers 84 
describing original data on a human disorder (MDD) are being appropriately cited by 85 
subsequent animal-based papers. It is important to mention that animal models are 86 
extensively used in MDD research. In fact, by the time our study was conducted there 87 
were about twice as many original papers using animal models in MDD research than 88 
papers using in vitro and in silico approaches.  89 
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During studies focused on MDD, animals frequently undergo severe procedures such as 90 
learned helplessness or forced swim test protocols. Most applicable legislations and 91 
guidelines mandate that such procedures should be avoided wherever possible. Hence it 92 
is reasonable to expect that the MDD-focused animal research community should be 93 
particularly alert to the data and insights provided by simpler data.  94 
Even though there is a wide consensus that the use of simpler models such as in vitro and 95 
in silico methods within basic and applied biomedical research helps animal researchers 96 
to meet the principles of Replacement (of animals with alternatives) and Reduction (of 97 
animal numbers), as described by Russell & Burch (1959), to our knowledge, there has 98 
never been a systematic study that empirically verifies whether animal researchers are, 99 
indeed, applying this principles to their practice i.e. if they are locating and using 100 
applicable data obtained via such simpler models.  101 
If in vitro and in silico studies are indeed seen as an important step prior to conducting 102 
animal studies in biomedical research, and animal studies are in turn seen as important 103 
prior to conducting human studies, then we would expect that papers describing in vitro 104 
or in silico data on a human disorder should be cited more frequently by animal papers, 105 
than by human medical papers. If, on the contrary, this is not the case, then further studies 106 
on other human disorders and drug development should be conducted to confirm the 107 
extent to which the contemporary theoretical paradigm for biomedical research is actually 108 
being followed in practice. If adherence is not as common as believed, then this paradigm 109 
should clearly be revised. 110 
 111 
2. Methods  112 
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We conducted a citation analysis as defined by Garfield and Merton (1979). Concisely, 113 
in a citation analysis, target papers are located first and then a search for all other papers 114 
citing the former is performed.  115 
The information compiled comprises the total number of citations, and the patterns of 116 
citation. We used a total of 67 target papers of in vitro or in silico studies on MDD- 117 
utilising only human data, selected from the citation analysis database created in our 118 
previous study (Carvalho et al., 2019a). The citation analysis was performed between 119 
September 2016 and June 2017. We considered all published papers using in vitro or in 120 
silico methods, that aimed to gain knowledge about MDD, and were published prior to 121 
2011, to enable five-year time for citations – a frequently used timeline for citation 122 
analysis (e.g. Wooding et al., 2014).  To locate target papers we searched PubMed – the 123 
largest freely accessible bibliographic database, using the following Medical Subject 124 
Heading (MeSH) search terms: ‘Depressive Disorder, Major’ AND (“in silico” OR 125 
‘computer model’ OR ‘mathematical model’ OR ‘computer simulation’ OR ‘in vitro’ OR 126 
‘cell culture’ OR ‘culture technique’ OR ‘cell line’ OR ‘organ culture’ OR ‘tissue 127 
culture’. Our goal was to select original publications that presented new data, so we used 128 
PubMed filters to exclude review articles (“review”, “systematic review”, “meta-129 
analysis”, “bibliography”) as well as opinion articles (“biography”, “autobiography”, 130 
“comment”, “editorial”, “interview”). We also excluded by hand in vitro papers that used 131 
animal tissue or cells. Using the citation tracking facility within Web of Science, we 132 
counted the number of times each target paper was cited by subsequent papers in the 133 
following categories: ̀ animal research papers`, ̀ human medical papers`, ̀ in vitro papers`, 134 
and `in silico papers`. Citing papers may have been assigned to more than one category 135 
if they described different research approaches (e.g. human-based and in vitro). 136 
 137 
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3. Results 138 
In total, 464 (18%) of the 2,574 citations received by the 38 in vitro papers were by 139 
invasive animal research papers, and 978 (40%) were by human medical papers. For the 140 
29 in silico papers, 44 (5%) of the 806 citations were by invasive animal research papers, 141 
and 317 (39%) by human medical papers. 142 
As shown in Fig. 2, the majority of citations received by both in vitro or in silico target 143 
papers were by papers employing the same research method, and by human medical 144 
papers. The proportion of citations by animal papers and the other research method were 145 
considerably lower. More importantly, the proportion of citations by animal papers was 146 
lower than by human medical papers. 147 
 148 
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 150 
Figure 2 . Boxplots of the proportion of citations received by research category for in 151 
vitro A) and in silico B) papers on MDD.  152 
 153 
4. Discussion 154 
The results of our citation analysis suggest that the standard approach to testing medical 155 
hypotheses – which postulates that in vitro and in silico research is an important step prior 156 
to conducting animal testing – is not supported by citation data, at least for MDD research. 157 
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Clearly, MDD biomedical research utilising in vitro and in silico data does not seem to 158 
be considered important by, or at least more important to, the animal research community, 159 
than it is to the human medical community. 160 
One can argue that if the animal research community is not citing in vitro and in silico 161 
papers on MDD, these might be of limited use. However, that is inconsistent with their 162 
substantial use by the human medical community, which cites more this kind of research 163 
than research based on animal studies (Carvalho et al., 2019a). Additionally, this lack of 164 
transferability of knowledge between the animal and the human medical research 165 
communities is further evidenced by the fact that, in general, most citations received by 166 
animal research papers are within other animal-based studies, rather than within human 167 
medical papers (e.g. Carvalho et al., 2019b).  168 
MDD is a complex human mental disorder with multifactorial aetiopathogenesis (Chiriţă 169 
et al., 2015), so one cannot extrapolate that the citation patterns found here will 170 
necessarily be replicated in other disorders that have just one cause (e.g. Down’s 171 
syndrome). Furthermore, a single disease analysis is not enough to generalize the results 172 
to the entire field of biomedical research.  173 
Hence, the next step should be the use of a similar approach targeting monofactorial 174 
disorders and drug trials. If, as whole, these studies produce similar results, then it would 175 
be compelling evidence that the accepted paradigm for biomedical research and drug 176 
discovery and development is not being sufficiently followed, which supports the claims 177 
made by several authors (e.g. Herrmann, 2019) that the 3Rs are not being addressed as 178 
well as required by applicable legislation and good research practice. This suggests that 179 
animal studies in biomedical research are mostly defining their research priorities 180 
autonomously, rather than being perfectly framed in the biomedical research paradigm. 181 
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Sixty years ago Russell and Burch (1959) established the foundations of much current 182 
legislation regarding animal experimentation, with the formulation of the 3R principles. 183 
Even though the research community unanimously welcomes them, the focus of their 184 
application has predominantly been refinement, and not always in an effective way 185 
(Herrmann, 2019).  186 
Nowadays there is an increasing number of databases on human and animal protein 187 
expression differences (for a review see Yin et al., 2020) which, on the one hand, makes 188 
it easier for researchers to locate and cite existing data; but, on the other hand, might 189 
stimulate animal research to be conducted independently of in vitro and in silico data to 190 
populate such databases.  191 
In theory, the reduction principle depends upon the standard use of in silico and in vitro 192 
techniques prior to animal studies. If original data on human disorders from in vitro and 193 
in silico approaches are not being used by the animal research community, then the 194 
reduction principle is not being properly fulfilled. The reasons behind this must surely be 195 
multiple: 196 
One of the possible reasons is the inadequacy of systematic reviews that animal 197 
researchers sometimes perform on their research topic, prior to conducting animal 198 
experiments. These should prevent unnecessary animal use (Leenaars et al., 2012), but 199 
by excluding from the search in vitro and in silico studies, researchers can exclude an 200 
important source of knowledge. 201 
Based on our results we recommend that changes are made in current systematic review 202 
protocols in order to include in vitro and in silico data. 203 
Another reason that became salient with our study and deserves attention, is that  in vitro 204 
and in silico approaches are, by definition, human-based methods, not animal-based 205 
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methods. Conceivably human data is not relevant enough for animal papers, in the same 206 
way animal studies do not seem to be relevant to subsequent human studies (Carvalho et 207 
al, 2019a,b).   208 
This highlights that the current paradigm of biomedical research and drug discovery and 209 
development includes two steps of knowledge transferability between the animal and the 210 
human models, neither of which appear to work well. If similar results are found in other 211 
disorders and more importantly, in drug discovery, than the current paradigm must be 212 
changed. Specifically, animal testing must be deprioritized, with greater investment in 213 
human-based in vitro and in silico research approaches. 214 
 215 
Acknowledgements 216 
This study was financed by Animalfree Research–Switzerland, and by Portuguese 217 
national funds through FCT–Fundação para a Ciência e a Tecnologia, within the CFCUL 218 
Unit funding UID/FIL/00678/2013. TAM thanks partial support by Centro de Estatística 219 
e Aplicações (CEAUL), funded by FCT - Fundação para a Ciência e a Tecnologia, 220 
Portugal, through the project UID/MAT/00006/2019). These funders played no role in 221 
study conception, design, data collection and analysis, manuscript authorship or the 222 
decision to submit for publication. 223 
 224 
References: 225 
Carvalho C, Varela SAM, Bastos LF, Órfão I, Beja V, Sapage M, et al. The Relevance of 226 
In silico, In vitro and Non-human Primate based Approaches to Clinical Research on 227 
12 
 
Major Depressive Disorder. ATLA. 2019a: 47 (3-4): 128-139. 228 
10.1177/0261192919885578. 229 
Carvalho C, Alves D, Knight A, Vicente L. Is animal-based biomedical research being 230 
used in its original context? In Herrman K, Jane K, editors.  Animal Experimentation: 231 
Working Towards a Paradigm Change. Boston: Brill., 2019b. pp. 376–390. 232 
doi.org/10.1163/9789004391192_017 233 
Chiriţă AL, Gheorman V, Bondari D, Rogoveanu I. Current understanding of the 234 
neurobiology of major depressive disorder. Rom J Morphol Embryol. 2015. 56(2 Suppl): 235 
651-658. 236 
Choudhuri S, Patton GW, Chanderbhan RF, Mattia A, Klaassen CD. From classical 237 
toxicology to Tox21: Some critical conceptual and technological advances in the 238 
molecular understanding of the toxic response beginning from the last quarter of the 20th 239 
century. Toxicological Sciences. 2017. 161(1): 5-22, 10.1093/toxsci/kfx186. 240 
Garfield E, Merton RK. Citation indexing: Its theory and application in science, 241 
technology, and humanities (Vol. 8). New York: Wiley; 1979. 242 
Herrmann K. Refinement on the way towards replacement: Are we doing what we can? 243 
In Herrman K, Jane K, editors. Animal Experimentation: Working Towards a Paradigm 244 
Change. Boston: Brill; 2019. pp. 1-64. https://doi.org/10.1163/9789004391192 245 
Leenaars M, Hooijmans CR, van Veggel N, Ter Riet G, Leeflang M, Hooft L, et al. A 246 
step-by-step guide to systematically identify all relevant animal studies. Laboratory 247 
animals: 2012: 46(1): 24-31. 10.1258/la.2011.011087. 248 
13 
 
Pound P, Ebrahim S, Sandercock S, Bracken MB, Roberts I. Where is the evidence that 249 
animal research benefits humans? BMJ: 2004: 328(7438): 514-517. 250 
10.1136/bmj.328.7438.514 251 
Russell WMS, Burch RL. The principles of humane experimental technique. London: 252 
Methuen; 1959. 253 
Taylor K. Recent developments in alternatives to animal testing. In Herrman K, Jane K, 254 
editors, Animal Experimentation: Working Towards a Paradigm Change (Boston: Brill; 255 
2019. Pp. 583–609.  10.1163/9789004391192_002 256 
Yin JY, Sun W, Li FC, Hong JJ, Li XX, et al. VARIDT 1.0: Variability of Drug 257 
Transporter Database. Nucleic Acids Research: 2020 48(D1): D1042-D1050. 258 
10.1093/nar/gkz779. 259 
Wooding S, Pollitt A, Castle-Clarke S, Cochrane G, Diepeveen S, et al. Mental Health 260 
Retrosight: Understanding the returns from research (lessons from schizophrenia): policy 261 
report. Rand health quarterly 2014. 4(1). Available et 262 
https://www.rand.org/pubs/research_reports/RR325.html.  263 
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin  DJ, et al. 264 
Guidelines for the welfare and use of animals in cancer research. British journal of cancer. 265 
2010: 102(11): 1555-1577. 266 
